Evercore ISI downgraded Hologic (HOLX) to In Line from Outperform with a price target of $78, down from $79.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic downgraded to Neutral from Outperform at BNP Paribas Exane
- Hologic’s Financial Health at Risk: Navigating Reimbursement and Guideline Challenges
- Hologic price target raised to $76 from $69 at Morgan Stanley
- Hologic Updates Restricted Stock Unit Award Agreement
- Cautious Hold Rating for Hologic Amid Strong Q4 Results and Future Uncertainties